Omeros Corporation   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Seattle WA United States (1994)

Organization Overview

First Clinical Trial
2007
NCT00599664
First Marketed Drug
2014
phenylephrine (Prefrin)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

OMEROS | Omeros Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atypical Hemolytic Uremic Syndrome (Phase 3)

Azotemia (Phase 3)

Calculi (Phase 2)

Cataract (Phase 4)

Glomerulonephritis, IGA (Phase 3)

Glomerulonephritis, Membranoproliferative (Phase 2)

Hemolysis (Phase 3)

Hemolytic-Uremic Syndrome (Phase 3)

Heroin Dependence (Phase 2)

Huntington Disease (Phase 2)

Kidney Calculi (Phase 2)

Kidney Diseases (Phase 3)

Lupus Nephritis (Phase 2)

Nephritis (Phase 2)

Nephrolithiasis (Phase 2)

Opioid-Related Disorders (Phase 2)

Schizophrenia (Phase 2)

Syndrome (Phase 3)

Thrombotic Microangiopathies (Phase 3)

Tobacco Use Disorder (Phase 2)

Urinary Calculi (Phase 2)

Urolithiasis (Phase 2)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 13